Insights

Clinical-stage cancer therapies Nuvalent, Inc. is a clinical-stage biopharmaceutical company specializing in creating precisely targeted therapies for kinase targets in cancer. This focus on innovative cancer treatments presents a prime sales opportunity for collaborations with healthcare institutions and oncology centers seeking advanced therapeutic options for their patients.

Recent investments and acquisitions With recent investments from Erste Asset Management GmbH and acquisition by Hudson Bay Capital Management LP, Nuvalent has demonstrated attractiveness to investors, potentially signaling financial stability and growth potential. Sales professionals could leverage this financial backing to introduce partnership or investment opportunities to interested parties.

Expanding pipeline and clinical trials Nuvalent's expanding pipeline with lead programs in ROS1-positive and ALK-positive NSCLC, coupled with the commencement of Phase 2 clinical trials, showcases a strong commitment to research and development. Sales development representatives could target biotech companies, research institutions, and clinical trial centers for potential collaborations or supply agreements.

Key personnel appointments The promotion of Henry Pelish to Chief Scientific Officer indicates a strategic leadership enhancement within Nuvalent. This presents an opportunity for sales professionals to engage with key decision-makers and explore partnerships, licensing opportunities, or joint ventures under the guidance of a seasoned scientific leader.

Market recognition and operating plan Nuvalent's recent market recognition through the launch of OnTarget 2026 and investments from entities like Arizona State Retirement System highlight industry acknowledgment of the company's potential. Sales professionals could leverage this industry validation to engage potential partners, investors, and collaborators looking to align with a promising player in the biotechnology sector.

Similar companies to Nuvalent, Inc.

Nuvalent, Inc. Tech Stack

Nuvalent, Inc. uses 8 technology products and services including LinkedIn Recruiter, SAS/GRAPH, SAS, and more. Explore Nuvalent, Inc.'s tech stack below.

  • LinkedIn Recruiter
    Applicant Tracking Systems
  • SAS/GRAPH
    Business Intelligence
  • SAS
    Business Intelligence
  • Cloudflare
    Content Management System
  • Google Cloud
    Infrastructure As A Service
  • HTML
    Programming Languages
  • Smartsheet
    Project Management
  • Genesis theme
    Web Platform Extensions

Media & News

Nuvalent, Inc.'s Email Address Formats

Nuvalent, Inc. uses at least 1 format(s):
Nuvalent, Inc. Email FormatsExamplePercentage
FLast@nuvalent.comJDoe@nuvalent.com
33%
First.Last@nuvalent.comJohn.Doe@nuvalent.com
17%
FLast@nuvalent.comJDoe@nuvalent.com
33%
First.Last@nuvalent.comJohn.Doe@nuvalent.com
17%

Frequently Asked Questions

Where is Nuvalent, Inc.'s headquarters located?

Minus sign iconPlus sign icon
Nuvalent, Inc.'s main headquarters is located at One Broadway 14th Floor Cambridge, Massachusetts 02142 US. The company has employees across 1 continents, including North America.

What is Nuvalent, Inc.'s stock symbol?

Minus sign iconPlus sign icon
Nuvalent, Inc. is a publicly traded company; the company's stock symbol is NUVL.

What is Nuvalent, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
Nuvalent, Inc.'s official website is nuvalent.com and has social profiles on LinkedIn.

How much revenue does Nuvalent, Inc. generate?

Minus sign iconPlus sign icon
As of November 2024, Nuvalent, Inc.'s annual revenue reached $3.8M.

What is Nuvalent, Inc.'s SIC code NAICS code?

Minus sign iconPlus sign icon
Nuvalent, Inc.'s SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does Nuvalent, Inc. have currently?

Minus sign iconPlus sign icon
As of November 2024, Nuvalent, Inc. has approximately 141 employees across 1 continents, including North America. Key team members include Chief Financial Officer: A. B.Chief Scientific Officer: H. P.Chief Medical Officer: C. D. T.. Explore Nuvalent, Inc.'s employee directory with LeadIQ.

What industry does Nuvalent, Inc. belong to?

Minus sign iconPlus sign icon
Nuvalent, Inc. operates in the Biotechnology Research industry.

What technology does Nuvalent, Inc. use?

Minus sign iconPlus sign icon
Nuvalent, Inc.'s tech stack includes LinkedIn RecruiterSAS/GRAPHSASCloudflareGoogle CloudHTMLSmartsheetGenesis theme.

What is Nuvalent, Inc.'s email format?

Minus sign iconPlus sign icon
Nuvalent, Inc.'s email format typically follows the pattern of . Find more Nuvalent, Inc. email formats with LeadIQ.

How much funding has Nuvalent, Inc. raised to date?

Minus sign iconPlus sign icon
As of November 2024, Nuvalent, Inc. has raised $575M in funding. The last funding round occurred on Sep 16, 2024 for $575M.

When was Nuvalent, Inc. founded?

Minus sign iconPlus sign icon
Nuvalent, Inc. was founded in 2017.
Nuvalent, Inc.

Nuvalent, Inc.

Biotechnology ResearchMassachusetts, United States51-200 Employees

Nuvalent is creating precisely targeted therapies for patients with cancer designed to overcome the limitations of existing therapies for clinically proven kinase targets. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com.

Section iconCompany Overview

Headquarters
One Broadway 14th Floor Cambridge, Massachusetts 02142 US
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
NUVL
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2017
Employees
51-200

Section iconFunding & Financials

  • $575M

    Nuvalent, Inc. has raised a total of $575M of funding over 5 rounds. Their latest funding round was raised on Sep 16, 2024 in the amount of $575M.

  • $10M

    Nuvalent, Inc.'s revenue is in the range of $10M

Section iconFunding & Financials

  • $575M

    Nuvalent, Inc. has raised a total of $575M of funding over 5 rounds. Their latest funding round was raised on Sep 16, 2024 in the amount of $575M.

  • $10M

    Nuvalent, Inc.'s revenue is in the range of $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.